Parasites, Hosts and Diseases

The Korea Society for Parasitology and Tropical Medicine (대한기생충학·열대의학회)
권호 표지
DOI QR코드

DOI QR Code

High Levels of Antibodies to Plasmodium falciparum Liver Stage Antigen-1 in Naturally Infected Individuals in Myanmar

  • Lee, Hyeong-Woo (Division of Malaria and Parasitic Diseases, National Institute of Health, Korea Centers for Disease Control and Prevention) ;
  • Moon, Sung-Ung (Division of Malaria and Parasitic Diseases, National Institute of Health, Korea Centers for Disease Control and Prevention) ;
  • Kim, Yeon-Joo (Division of Malaria and Parasitic Diseases, National Institute of Health, Korea Centers for Disease Control and Prevention) ;
  • Cho, Shin-Hyeong (Division of Malaria and Parasitic Diseases, National Institute of Health, Korea Centers for Disease Control and Prevention) ;
  • Lin, Khin (Vector Borne Diseases Control Project, Department of Health) ;
  • Na, Byoung-Kuk (Department of Parasitology and Institute of Health Sciences, Gyeongsang National University College of Medicine) ;
  • Kim, Tong-Soo (Division of Malaria and Parasitic Diseases, National Institute of Health, Korea Centers for Disease Control and Prevention)
  • Published : 2008.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Plasmodium falciparum liver stage antigen-1 (PfLSA-1) is one of the few antigens expressed exclusively in liver stage parasites. In this study, we evaluated the antibody responses against recombinant PfLSA-1 in naturally infected individuals in Myanmar. High levels of antibody responses (70.7%) were detected in 82 serum samples from 116 infected individuals, and IgG responses to PfLSA-1 principally composed of responses of IgG1 and IgG3 subclasses. These results show that PfLSA-1 elicits effective antibody responses in individuals infected with P. falciparum, and thus it could be not only an attractive candidate protein for vaccine development, but also a useful antigen for serodiagnosis of the infection.

Keywords

References

  1. Guerin-Marchand C, Druilhe P, Galey B, Londono A, Patarapotikul J, Beaudoin RL, Dubeaux C, Tartar A, Mercereau-Puijalon O, Langsley G. A liver-stage-specific antigen of Plasmodium falciparum characterized by gene cloning. Nature 1987; 329: 164-167 https://doi.org/10.1038/329164a0
  2. Hollingdale MR, Aikawa M, Atkinson CT, Ballou WR, Chen GX, Li J, Meis JF, Sina B, Wright C, Zhu JD. Non-CS pre-erythrocytic protective antigens. Immunol Lett 1990; 25: 71-76 https://doi.org/10.1016/0165-2478(90)90094-7
  3. Connelly M, King CL, Bucci K, Walters S, Genton B, Alpers MP, Hollingdale M, Kazura JW. T-cell immunity to peptide epitopes of liver-stage antigen 1 in an area of Papua New Guinea in which malaria is holoendemic. Infect Immun 1997; 65: 5082-5087
  4. Joshi SK, Bharadwaj A, Chatterjee S, Chauhan VS. Analysis of immune response against T-and B-cell epitopes from Plasmodium falciparum liver stage antigen 1 in rodent malaria models and malaria exposed human subject in India. Infect Immun 2000; 68: 141-150 https://doi.org/10.1128/IAI.68.1.141-150.2000
  5. Kurtis JD, Hollingdale MR, Luty AJ, Lanar DE, Krzych U, Duffy PE. Pre-erythrocytic immunity to Plasmodium falciparum: the case for an LSA-1 vaccine. Trends Parasitol 2001; 17: 219-223 https://doi.org/10.1016/S0169-4758(00)01862-7
  6. Taylor-Robinson AW. Immunity to liver stage malaria: considerations for vaccine design. Immunol Res 2003; 27: 53-70 https://doi.org/10.1385/IR:27:1:53
  7. Fidock DA, Gras-Masse H, Lepers JP, Brahimi K, Benmohamed L, Mellouk S, Guerin-Marchand C, Londono A, Raharimalala L, Meis JF, Langsley G, Roussilhon C, Tartar A, Druilhe P. Plasmodium falciparum liver stage antigen-1 is well conserved and contains potent B and T cell determinants. J Immunol 1994; 153: 190-204
  8. Na BK, Park JW, Lee HW, Lin K, Kim SH, Bae YA, Sohn WM, Kim TS, Kong Y. Characterization of Plasmodium vivax heat shock protein 70 and evaluation of its value for serodiagnosis of tertian malaria. Clin Vaccine Immunol 2007; 14: 320-322 https://doi.org/10.1128/CVI.00424-06
  9. Lee HW, Moon SU, Ryu HS, Kim YJ, Cho SH, Chung GT, Lin K, Na BK, Kong Y, Chung KS, Kim TS. Usefulness of the recombinant liver stage antigen-3 for an early serodiagnosis of Plasmodium falciparum infection. Korean J Parasitol 2006; 44: 49-54 https://doi.org/10.3347/kjp.2006.44.1.49
  10. Orlandi-Pradines E, Penhoat K, Durand C, Pons C, Bay C, Pradines B, Fusai T, Josse R, Dubrous P, Meynard JB, Durand JP, Migliani R, Boutin JP, Druilhe P, Rogier C. Antibody responses to several malaria pre-erythrocytic antigens as a marker of malaria exposure among travelers. Am J Trop Med Hyg 2006; 74: 979-985
  11. John CC, Tande AJ, Moormann AM, Sumba PO, Lanar DE, Min XM, Kazura JW. Antibodies to pre-erythrocytic Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children. J Infect Dis 2008; 197: 519-526 https://doi.org/10.1086/526787
  12. Lin K. Malaria control in Myanmar. In Kano S, Tongol-Rivera P eds, Asian Parasitology Vol. 6. Malaria in Asia. Chiba, Japan. Federation of Asian Parasitologists. 2005, p 123-134
  13. John CC, Ouma JH, Sumba PO, Hollingdale MR, Kazura JW, King CL. Lymphocyte proliferation and antibody responses to Plasmodium falciparum liver-stage antigen-1 in a highland area of Kenya with seasonal variation in malaria transmission. Am J Trop Med Hyg 2002; 66: 372-378 https://doi.org/10.4269/ajtmh.2002.66.372
  14. John CC, Zickafoose JS, Sumba PO, King CL, Kazura JW. Antibodies to the Plasmodium falciparum antigens circumsporozoite protein, thrombospondin-related adhesive protein, and liverstage antigen 1 vary by ages of subjects and by season in a highland area of Kenya. Infect Immun 2003; 71: 4320-4325 https://doi.org/10.1128/IAI.71.8.4320-4325.2003
  15. Wipasa J, Elliott S, Xu H, Good MF. Immunity to asexual blood stage malaria and vaccine approaches. Immunol Cell Biol 2002; 80: 401-414 https://doi.org/10.1046/j.1440-1711.2002.01107.x
  16. Wahlgren M, Berzins K, Perlmann P, Persson M. Characterization of the humoral immune response in Plasmodium falciparum malaria. II. IgG subclass levels of anti-P. falciparum antibodies in different sera. Clin Exp Immunol 1983; 54: 135-142
  17. Bouharoun-Tayoun H, Druilhe P. Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity. Infect Immun 1992; 60: 1473-1481
  18. Ferreira MU, Kimura EA, Katzin AM, Santos-Neto LL, Ferrari JO, Villalobos JM, de Carvalho ME. The IgG-subclass distribution of naturally acquired antibodies to Plasmodium falciparum, in relation to malaria exposure and severity. Ann Trop Med Parasitol 1998; 92: 245-256 https://doi.org/10.1080/00034989859807
  19. Aidoo M, Lalvani A, Allsopp CE, Plebanski M, Meisner SJ, Krausa P, Browning M, Morris-Jones S, Gotch F, Fidock DA, Takiguchi M, Robson KJH, Greenwood BM, Druilhe P, Whittle HC, Hill AVS. Identification of conserved antigenic components for a cytotoxic T-lymphocyte-inducing vaccine against malaria. Lancet 1995; 345: 1003-1007 https://doi.org/10.1016/S0140-6736(95)90754-8
  20. Doolan DL, Hoffman SL. The complexity of protective immunity against liver-stage malaria. J Immunol 2000; 165: 1453-1462 https://doi.org/10.4049/jimmunol.165.3.1453

Cited by

  1. Comparison of the antibody responses to Plasmodium vivax and Plasmodium falciparum antigens in residents of Mandalay, Myanmar vol.10, pp.None, 2008, https://doi.org/10.1186/1475-2875-10-228